Immunotherapy Use in Advanced Urothelial Carcinoma

Talazoparib Plus Enzalutamide Improves rPFS Regardless of AR Alteration Status in mCRPC

Olaparib Plus Pembrolizumab Shows Efficacy in HRR Gene–Mutated Advanced Tumors With/Without HRD Positivity

First-Line Penpulimab Plus Chemo Extends PFS in Recurrent or Metastatic Nasopharyngeal Carcinoma

TARA-002 Showcases Early Clinical Activity in BCG-Naive and -Unresponsive High-Risk NMIBC